Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow CUMBERLAND PHARMACEUTICALS INC

Get SEC filing alerts via email and in your feed for CUMBERLAND PHARMACEUTICALS INC

CPIX

CUMBERLAND PHARMACEUTICALS INC

About CUMBERLAND PHARMACEUTICALS INC

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription medicines for hospital, gastroenterology, and oncology markets. Its portfolio includes FDA-approved products like Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. The company leverages targeted sales forces, strategic partnerships, and international licensing to deliver innovative treatments that address unmet medical needs and improve patient care.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from CUMBERLAND PHARMACEUTICALS INC

1
1
CUMBERLAND PHARMACEUTICALS INC Cumberland Pharmaceuticals Reports 22% Revenue Decline and Operating Loss in Q1 2026

Via official filing (AI summary) | 27 days ago | 0 comments

2
1
CUMBERLAND PHARMACEUTICALS INC Cumberland Pharmaceuticals Reports 17.6% Revenue Growth to $44.5 Million for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
CUMBERLAND PHARMACEUTICALS INC Cumberland Pharmaceuticals Reports Q3 2025 Financial Results with $8.3M Revenue

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
CUMBERLAND PHARMACEUTICALS INC Cumberland Pharmaceuticals Reports 10% Revenue Growth to $10.8 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
CUMBERLAND PHARMACEUTICALS INC Cumberland Pharmaceuticals Reports 38% Revenue Increase to $11.7 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
CUMBERLAND PHARMACEUTICALS INC Cumberland Pharmaceuticals Reports $37.9 Million Revenue for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
CUMBERLAND PHARMACEUTICALS INC Cumberland Pharmaceuticals Reports Decline in Net Revenues and Increased Net Losses for Q3 and Nine Months Ended September 30, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments